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1. The dilemma
Despite the introduction of modern antiepileptic drugs (AEDs)
such as lamotrigine or topiramate, sodium valproate (VPA) is seen
by many as the most effective medication for seizure control in
idiopathic generalized epilepsy (IGE). The case vignettes and the
great review by Mole et al.1 in this issue dramatically illustrate the
ill effects of withholding VPA for seizure control and the
therapeutic beneﬁts of VPA. That is however only one side of
the coin.
The other side of the coin is that we have learnt in the last
30 years that VPA is the most teratogenic epilepsy drug on the
market with an overall risk of 11% for major congenital
malformations.2 VPA monotherapy is associated with signiﬁ-
cantly increased risks for six speciﬁc malformations including
spina biﬁda 12.7-fold increased risk for spina biﬁda.3 Although
alarming, this is not new. Preliminary case reports were
published as early in the mid-1980s.4 In addition, Meador and
colleagues5 have convincingly shown in recent years that
exposure to VPA during early pregnancy causes long-lasting
intelligence deﬁcits in the offspring.5 The effect was dose
dependent, and the impact of the effect appeared greater in
verbal than in nonverbal abilities.5
Given these risks, physicians are justiﬁably reluctant to
recommend VPA in young women with generalized epilepsy
unless contraceptive measures are taken. Yet, the merit of the
opinion piece by Mole et al.,1 is that it they reminded us that
indiscriminately withholding VPA in young women with general-
ized epilepsy may not be the best solution, either. How can we get
out of this dilemma?
2. Ways out of the dilemma
There is general agreement that, if possible, VPA should be
avoided in the ﬁrst trimester of pregnancy due to the risks.6 If this
is not possible, when, for example, prior attempts to lower the
dose or to stop VPA altogether have been unsuccessful, women
should be warned that stopping or lowering the dose of VPA
should not be done without consultation with her physician. Once
it has been determined that VPA needs to be continued during
pregnancy, the patient must be informed of the relative risks
including the general side-effect proﬁle of VPA, particularly
weight gain, and counseled appropriately. Counseling about the
teratogenic risks of major congenital malformations shouldhttp://dx.doi.org/10.1016/j.seizure.2014.10.004
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reinclude the important information that the vast majority of
children will be unaffected.
If VPA is needed, it should preferably be given prior to or during
pregnancy at daily doses not exceeding 1000 mg. This recommen-
dation is based on evidence suggesting that the teratogenic risk of
VPA seems to be higher at daily doses beyond 1000 mg.7
If 800–1000 mg/day of VPA do not achieve seizure-freedom, it is
better to ﬁnd this out prior to than during pregnancy, if possible. It
is reassuring in that respect that pregnancy itself does not seem to
substantially affect seizure control.8 Whether absence or myo-
clonic seizures and self-limiting, brief tonic-clonic-seizures affect
the health and the development of the child in utero, is not well
known. However, prolonged seizures and status epilepticus are
thought to be a serious threat to both mother and fetus according
to a case report.9 Most physicians seem to prefer to add another
suitable AED, if needed for seizure control, and shy away from
removing VPA during pregnancy (as any other AED).
As a caveat, it should be noted that the best evidence for the
usefulness of any of these treatment options during pregnancy is
largely anecdotal as in any patient with refractory generalized
epilepsy. Folate supplementation (at least 0.4 mg folic acid/day) is
generally recommended during conception and pregnancy al-
though the proper dose and the treatment effect, if any, is not well
known.6
In summary, navigating VPA treatment in women with
generalized epilepsy who need it, by protecting from teratogenic
risks and yet maintaining or achieving seizure control requires an
individualized balance. Mole and colleagues1 are commended to
have reminded us that a one-sided approach to ban sodium
valproate from the treatment of women with generalized epilepsy
may not always be in the best interest of the patient.
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